Sign in Subscribe
Universities and colleges

New Insights into Cancer Immunotherapy: A-Galactosylceramide-Pulsed Dendritic Cell Therapy

Strategic Insights

— 1 min read

Researchers at Chiba University in Japan have made new discoveries in cancer immunotherapy. A study published in Cancer Science found that patients with non-small-cell lung cancer (NSCLC) who received a-galactosylceramide-pulsed dendritic cell therapy experienced a prolonged overall survival time. The researchers identified two genes, LTB4DH and DPYSL3, as potential biomarkers for predicting a good immune response to the therapy.

Key Takeaways:

  • The study focused on the interferon-γ (IFN-γ) response of lung cancer patients undergoing a-galactosylceramide-pulsed dendritic cell therapy.
  • Six patient samples were included in the microarray analysis, with three subjects in the good responder group and three in the poor responder group.
  • Genes differentially expressed between pre-treatment and post-treatment samples were selected for analysis, and four genes were selected for further study.
  • Two genes, LTB4DH and DPYSL3, were confirmed to be candidate genes for predicting a good immune response to the therapy.
  • The expression profile of these two genes may be associated with the responsiveness of IFN-γ production after aGalCer-pulsed DC treatment.
  • K. Okita and colleagues published their study in Cancer Science, highlighting the potential of a-galactosylceramide-pulsed dendritic cell therapy in cancer treatment.

Statistics:

  • Two-fold increase in IFN-γ production was observed in patients with good responder status.
  • Six patient samples were analyzed in the microarray study.
  • Four genes were selected for further study after microarray analysis.
  • Two genes, LTB4DH and DPYSL3, were confirmed to be candidate genes for predicting a good immune response to the therapy.
  • The study focused on 8 patient samples, with 2 patients in the good responder group and 6 patients in the poor responder group.

Sources:

  • Okita, K., et al. (2010). A set of genes associated with the interferon-γ response of lung cancer patients undergoing a-galactosylceramide-pulsed dendritic cell therapy. Cancer Science, 101(11), 2333-2340.
  • Clinical Trials Week editors (2010, November 10). Cancer Immunotherapy Success. NewsRx.com.

Read more